Background: HCC, a poor-prognosis disease for which the only approved drug is sorafenib, has a high unmet need.Factors associated with tumor aggressiveness in advanced HCC include c-Met amplification/
Objective: Colorectal cancer (CRC) is one of the most common malignant tumors.Most of advanced CRC will progress after first-line treatment;therefore, seeking an efficient and low toxic maintaining re
Objective: To evaluate the potential utility of circulating tumor cells (CTCs) measurements in predicting prognosis of hepatocellular carcinoma (HCC) patients received trans arterial chemoembolization
Objective: Although it has been shown that polymorphisms in one-carbon metabolism (OCM) pathway are associated with gastric cancer (GC), their interactions and contributions for patients survival are
Objective: To avoid the damage of radiotherapy for rectal cancer patients, we have designed a phase Ⅱ study comparing Neoadjuvant mFOLFOX6 chemotherapy with or without radiation in locally advanced re
目的： The combination of nab-paclitaxel and cisplatin as preoperative treatment for esophageal squamous cell carcinoma (ESCC) has not been investigated.
目的：分析KRAS,NRAS,BRAF突变情况与结直肠癌患者的临床病理学特征,特别是转移的发生发展进程的关系。方法：序列分析法检测384例结直肠患者的KRAS外显子2,3,4,NRAS外显子2,3,4,BRAF外显子15的突变,并回顾性分析KRAS,NRAS,BRAF突变情况与临床病理学特点间的联系,探讨其与转移方式的关系。
目的：旨在探讨高增殖活性的NET的临床病理学特征以及不同治疗方案的疗效，为今后的临床实践提供参考。方法：本研究回顾性分析2012年1月-2015年3月就诊于解放军307医院消化肿瘤内科、中日友好医院中西医肿瘤内科和北京协和医院肿瘤内科高增殖活性的NET(分化良好的胃肠胰神经内分泌癌(G3))病例共28例，对临床病理特征以及治疗情况进行分析。
目的：局部进展期直肠癌的新辅助治疗标准方案是单药5-氟尿嘧啶联合放疗，但对远处转移控制不佳，增强化疗强度能否提高远处控制值得研究；另一方面，标准治疗影响患者的肛门功能和性功能，且术后的并发症发生率高，单纯新辅助化疗后选择性应用放疗也值得探索。
目的：按照国家食品药品监督管理总局(CFDA)批件的要求，在国产雷替曲塞(赛维健上市后，进一步观察和评价其单药用于不能耐受或不适合5-FU/CF治疗的局部晚期或复发转移性结直肠癌的安全性和有效性。